MiniMed reported fiscal first-quarter revenue of $843 million, up 15.8% organically, and raised its full-year organic revenue growth outlook to approximately 10.5% from 10%. The company, which became a stand-alone public company in early March after its IPO, saw U.S. revenue grow 13.1% and international revenue rise 16.9%, with the extra week in the fiscal calendar contributing 4 to 6 points to growth. Adjusted EBITDA was $83 million, a margin of 9.9%, including a 230-basis-point impact from accelerated investments and a nonoperational FX charge. CEO Que Dallara highlighted the successful launch of the MiniMed Flex pump, which drove U.S. new pump sales up over 20%, and announced that the MiniMed Fit patch pump has been submitted to the FDA ahead of schedule, with a full U.S. launch expected by summer 2027. The company also completed enrollment in the U.S. pivotal trial for its Vivera fully closed-loop algorithm, with a launch expected in the second half of calendar 2027, and received IDE approval for a next-generation extended wear sensor.
MiniMed Group, Inc. Common StockStrong Q1 revenue growth and raised outlook driven by successful MiniMed Flex pump launch and new product pipeline.
